Form 8-K

8-K — Enveric Biosciences, Inc.

Accession: 0001493152-26-020410

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000890821

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

GRAPHIC (ex99-1_003.jpg)

GRAPHIC (ex99-1_004.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000890821

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

April

30, 2026

Date

of Report (Date of earliest event reported)

Enveric

Biosciences, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38286

95-4484725

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

Enveric

Biosciences, Inc.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA, 02142

(Address

of principal executive offices) (Zip code)

Registrant’s

telephone number, including area code: (617) 444-8400

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.01 per share

ENVB

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

April 14, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), filed a definitive proxy statement on

Schedule 14A (the “Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) for the 2026 Annual

Meeting of Stockholders of the Company (the “Annual Meeting”), which will be held on Thursday, May 28, 2026, at 10:00 a.m.,

Eastern Time. The Annual Meeting is being held for the following purposes:

elect six directors to serve until the Company’s 2027 Annual Meeting of Stockholders or until their successors are duly elected

and qualified (“Election of Directors”);

approve by a non-binding advisory vote the compensation of the Company’s named executive officers, as disclosed in the Proxy

Statement (the “Say-on-Pay Proposal”);

extend the approval of the Board of Directors of the Company (the “Board”) to amend the Company’s Amended and Restated

Certificate of Incorporation, as amended (the “Charter”), in substantially the form attached to the Proxy Statement as

Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding

common stock, par value $0.01 per share (“Common Stock”), including stock held by the Company as treasury shares, at

a ratio of 1-for-5 to 1-for-15 (the “Range”), with the ratio within such Range to be determined at the discretion of

the Board and included in a public announcement (a “Reverse Stock Split” and the “Reverse Stock Split Proposal”);

extend the approval of the Board to amend the Charter, in substantially the form attached to the Proxy Statement as Annex B, to,

at the discretion of the Board, increase the authorized number of shares of our Common Stock from 100,000,000 to 5,000,000,000 shares

(“Authorized Stock Increase Proposal”);

ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year

ending December 31, 2026 (the “Auditor Ratification Proposal”);

approve a complete or partial adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation

and vote of proxies in the event there are not sufficient votes in favor of the foregoing proposals or to establish a quorum (the

“Adjournment Proposal”); and

transact such other business that is properly presented at the Annual Meeting.

The

Proxy Statement contained typographical errors with respect to the Range in the Reverse Stock Split Proposal. The Range of the Reverse

Stock Split is incorrectly described in two sections of the Proxy Statement, the proxy card and the Notice of Internet Availability of

Proxy Materials as 1-for-5 to 1-for-50. The correct Range is 1-for-5 to 1-for-15. Accordingly, the Company determined to amend and supplement

the Proxy Statement as described in this Current Report on Form 8-K.

April 30, 2026, the Company filed additional proxy materials on Schedule 14A (the “Additional Proxy Materials”) with the

SEC to correct the typographical errors in the Proxy Statement and supplement the disclosures therein. Specifically, the Additional Proxy

Materials clarify that the Range of the Reverse Stock Split Proposal is 1-for-5 to 1-for-15.

There

is no change to the location, the record date, or any of the other proposals to be acted upon at the Annual Meeting.

The

foregoing description of the Additional Proxy Materials is qualified in its entirety by reference to the full text of the Additional

Proxy Materials, a copy of which is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Additional Proxy Materials

104

Cover

Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

April 30, 2026

ENVERIC

BIOSCIENCES, INC.

By:

/s/

Joseph Tucker

Joseph

Tucker, Ph.D.

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

April

30, 2026

Dear

Enveric Biosciences, Inc. Stockholder,

are writing to inform you of an important update regarding our 2026 Annual Meeting of Stockholders. After the distribution of our definitive

proxy statement, dated April 14, 2026, we identified a typographical error.

ensure you have the most accurate and complete information, we have filed additional definitive proxy materials with the Securities and

Exchange Commission and are providing you with a corrected version of the relevant sections. These updates do not change the meeting

date, time, or location:

Meeting

Details:

●

Date:

Thursday, May 28, 2026

●

Time:

10:00 a.m.

●

Location:

www.virtualshareholdermeeting.com/ENVB2026 (enter the 16-digit control number on your proxy card or voting instruction form)

encourage you to review the enclosed materials carefully before voting. If you have already voted, you may change your vote by following

the instructions in the proxy materials.

Your

participation is important to us, and we appreciate your attention to this matter. If you have any questions, please contact our proxy

solicitor, Kingsdale Advisors, by telephone at 1-866-581-1570 (stockholders) and 646-741-3433 (brokers, banks and other nominees), or

by email at contactus@kingsdaleadvisors.com.

Thank

you for your continued support of Enveric Biosciences, Inc.

Sincerely,

Joseph

Tucker, Ph.D.

Chief

Executive Officer and Director

ENVERIC

BIOSCIENCES, INC.

245

First Street, Riverview II, 18th Floor

Cambridge,

MA 02142

SUPPLEMENT

TO PROXY STATEMENT FOR

THE

ANNUAL MEETING OF STOCKHOLDERS

Be Held May 28, 2026

Explanatory

Note

April 14, 2026, Enveric Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” “Enveric,”

or the “Company”), filed a definitive proxy statement (“Proxy Statement”) for its 2026 Annual Meeting of Stockholders

(“Annual Meeting”), to be held at 10:00 a.m. Eastern Time on May 28, 2026. This supplement (“Supplement”) to

the Proxy Statement supplements the Proxy Statement as filed and should be read in conjunction with the Proxy Statement and any other

additional proxy materials we have filed.

The

purpose of this Supplement is to correct typographical errors with respect to the maximum ratio of the proposed reverse stock split range

in Proposal 3. Proposal 3 in the Proxy Statement requests stockholder approval to extend the approval of the Board of Directors (the

“Board”) to amend the Company’s Amended and Restated Certificate of Incorporation, as amended, to, at the discretion

of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding common stock, including stock held

by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-15 (the “Range”), with the ratio within such Range to be

determined at the discretion of the Board and included in a public announcement. In two locations within the Proxy Statement, and specifically

on the proxy card (“Proxy Card”) and in the notice of Internet availability (“Notice”) that were mailed to stockholders,

the maximum ratio of the proposed reverse stock split range was incorrectly stated at 1-for-50. The correct maximum ratio intended by

the Board, and which was accurately stated in the text of Proposal 3 within the Proxy Statement itself, starting on page 34, is 1-for-15.

THIS

SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

EXCEPT

AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN

THE PROXY STATEMENT.

This

Supplement supplements and updates the disclosures in the Proxy Statement as follows:

●

All

references in the Proxy Statement to “1-for-50” are replaced with “1-for-15”.

●

The

foregoing updates apply to the Proxy Card and Notice. The entirety of the revised Proxy Card and Notice are reproduced below:

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (523367 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (580208 bytes)

Download ex99-1_002.jpg

GRAPHIC

Filename: ex99-1_003.jpg · Sequence: 5

Binary file (501604 bytes)

Download ex99-1_003.jpg

GRAPHIC

Filename: ex99-1_004.jpg · Sequence: 6

Binary file (382735 bytes)

Download ex99-1_004.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-38286

Entity Registrant Name

Enveric

Biosciences, Inc.

Entity Central Index Key

0000890821

Entity Tax Identification Number

95-4484725

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Enveric

Biosciences, Inc.

Entity Address, Address Line Two

245

First Street, Riverview II

Entity Address, Address Line Three

18th Floor

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02142

City Area Code

(617)

Local Phone Number

444-8400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.01 per share

Trading Symbol

ENVB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration